This genetic layer does not predict exact medication response but can support more informed conversations between patient and provider about expected tolerability and efficacy trajectories, potentially guiding dose escalation strategy or selection among dual-peptide formulations
Proof-of-concept that network pharmacology is effective to modify development of acquired temporal lobe epilepsy
Cardiovascularkidneymetabolic health: a presidential advisory from the American Heart Association
Plan for Maintenance Address plateaus, goal-weight transition, medication reassessment and prevention of weight regain
How they work (simple): trigger insulin when you eat, curb glucagon, delay gastric emptying , and reduce appetite/satiety signals useful for type 2 diabetes and, for certain formulations, chronic weight management
Heres an excerpt from the study: Genotype and allele frequencies of the MTHFR +677C/T and +1298A/C polymorphisms showed no significant differences between healthy controls and patients with AITD
